Australia’s audit office will probe the Morrison government’s $2 billion deal with US pharmaceutical giant Moderna to set up vaccine manufacturing in Australia.
The R&D tax offset has served as a life raft for some of Australia’s most prominent technology start-ups,though in some cases it wasn’t enough.
Rate-sensitive sectors including consumer stocks dragged the local sharemarket lower,despite a US equities rebound overnight following its steep sell-off.
Investors have punished the company’s share price for the second day in a row – despite it booking revenue of $12.3 billion for the half-year to December 31.
Shares in the blood plasma treatments maker were trading nearly 5 per cent lower following the results.
From garbage collection to race car manufacturing,nine fund managers at some of Australia’s largest investment firms have given their best stock picks.
From health to fast food,investors are starting to question which companies will be slimmed thanks to weight-loss drugs.
CSL has outlined its growth strategy to investors and played down concerns about weight-loss drugs’ impact on some of its key products.
Shareholders have grilled the biotech giant about its long-term strategy as the stock sits close to 10 per cent lower for the year.
The ASX heavyweight and the nation’s largest healthcare company is looking to make its operations more efficient to counter inflation and currency woes.
Blood plasma giant CSL will set the tone for earnings season this week,having been hit hard after a profit downgrade earlier this year.